Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 6/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.30 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.30 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.30 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18172356 | 0.93 | P2RY14 (0.35) | P2RY14P2RX3P2RX2DGAT1LMNA | |
| SCHEMBL18172390 | 0.92 | P2RY14 (0.35) | P2RY14P2RX3P2RX2DGAT1 | |
| SCHEMBL18172506 | 0.91 | P2RY14 (0.41) | P2RY14P2RX3P2RX2DGAT1 | |
| SCHEMBL18172421 | 0.90 | DGAT1 (0.40) | P2RY14P2RX3P2RX2DGAT1 | |
| SCHEMBL18172386 | 0.89 | P2RY14 (0.38) | P2RY14P2RX3P2RX2 | |
| SCHEMBL18184298 | 0.88 | P2RX3 (0.43) | P2RY14P2RX3P2RX2LMNA | |
| SCHEMBL18172493 | 0.87 | P2RY14 (0.48) | P2RY14LMNA | |
| SCHEMBL18172502 | 0.87 | P2RY14 (0.33) | P2RY14P2RX3P2RX2DGAT1 | |
| SCHEMBL18172457 | 0.86 | P2RY14 (0.36) | P2RY14P2RX3P2RX2 | |
| SCHEMBL18172392 | 0.83 | P2RY14 (0.40) | P2RY14P2RX3P2RX2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207449-B | Tetrazole derivatives for the treatment of psychotic disorders | 豪夫迈·罗氏有限公司 | 2020-11-10 | — | — | CN | claimed |
| US-20180297961-A1 | TETRAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-10-18 | — | — | US | claimed |
| CN-107207449-B | Tetrazole derivatives for the treatment of psychotic disorders | 豪夫迈·罗氏有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-10577332-B2 | Tetrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577332-B2 | Tetrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180297961-A1 | TETRAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3286182-A1 | TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | F. Hoffmann-La Roche AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016169902-A1 | TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016169902-A1 | TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577332-B2 | Tetrazole derivatives | MC2R, MC3R, GABRR3 | P2RY14 3175/4885P2RX3 1659/4885P2RX2 2779/4885 |
| US-20180297961-A1 | TETRAZOLE DERIVATIVES | MC2R, MC3R, GABRR3 | P2RY14 3175/4885P2RX3 1659/4885P2RX2 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.